Radiomics
    insight-based
    decision making

    About Radiomics

    Radiomics was founded in Liège in 2016 with the objective to extract all the information embedded in medical images utilizing biologically meaningful AI via our proprietary quantitative imaging biomarkers technology - Radiomics®.

    We offer our services to pharmaceutical and other treatment development companies. By using patented technologies, we extract radiomic features from standard medical images to provide sensitive pharmacodynamic endpoints, as well as an early patient stratification tool.

    Radiomics has the objective of supporting your decision making and reduce therapy development time.

    Mission  I  Vision  I  Values  I  Board

    Radiomics uses Artificial intelligence to unravel the gold mine of hidden data in standard medical images in order to support your drug development and marketing.

    Mission

    Our mission is to enable the right diagnosis & treatment for the right patient through quantitative imaging and machine learning. Radiomics harnesses the power of Artificial Intelligence to deliver accurate and robust clinical decision support systems based on standard clinical imaging.

    Vision

    A Belgium-based healthcare giant focusing on: accurate diagnostics, detailed therapy evaluation, sensitive prediction of treatment effect in oncology and other therapeutic areas. With an investment arm that takes promising new therapies up to end of phase 2.

    Make precision medicine a reality via AI & image analysis. 

    In any disease area where imaging is used, Radiomics adds value.

    Values

    Our team is the number one asset of the company. It is diverse, talented, complementary, empowered & supportive to each other. Each member has an intrinsic drive to be part in the challenge of transforming the world for patients, where every second counts. Attracting & developing talent is critical. Everyone will grow on the journey.

    We know why we are here, have clarity on the corporate strategy and goals, as well as solid expectations for every role. We take responsibility for delivering on them. Based on such clarity and strength, everyone feels empowered to apply one’s own judgement. 

    In our fast-paced environment, being in synch is paramount. Communication is therefore frequent, open, honest, respectful & direct. We value constructive feedback, “good and bad” and never hesitate to “kill the elephant in the room”.

    At Radiomics we celebrate our successes, no matter big or small, to drive both team bonding and personal development.

    Board

    Dimitri Liquet

    Business developer
    Dimitri is a business developer for SMART INDUSTRY BOOSTER, a subsidiary of NOSHAQ dedicated to Industry 4.0 development. He also works for NOSHAQ since 2018 as an Investment manager. Dimitri founded SPIAPS in 2009, a small company dedicated to process improvement and consultancy. He recently acted as an Data translator for a set of 7 User Cases of process oriented studies using Data Analytics in chemical industrial plants. Dimitri led several Lean Implementation Projects in the automotive, service and aeronautics industry leading to strong enhancement of plant capabilities. Formerly was CEO at TI Automotive industry, a medium size company, active in Steel coating and previously spent 15 years as Production Executive in several plants of Arcelor Mittal in Belgium.

    Bernard Surlemont

    Lorem ipsum
    After ten years of experience in international business and INSEAD MBA and PhD in Strategic Management, Bernard Surlemont became professor of entrepreneurship at Liège University (Belgium) and Lausanne (Switzerland). In 1988, he launched the TTO of Liège University. He was co-founder of Mithra Pharmaceuticals, the VC Fund E-Capital I, Epimede. In 2004 he launched the first Belgian master in entrepreneurship at HEC-ULiège. He is board member of several start-ups and VCs funds. In 2000 he created SEED (now EKLO), an incubator to coach High-growth potential startups. He is the founder of VentureLab, an incubator dedicated to support the creation of startups by students (www.venturelab.be). His expertise relies in scientific entrepreneurship, universities spin-offs and in entrepreneurial finance.

    Philippe Lambin

    Chief Scientific Advisor
    Philippe Lambin is a Clinician Radiation Oncologist, “ERC advanced & ERC PoC grant laureate” respectively from 2016 & 2017 and pioneer in translational research with a focus on tumour hypoxia and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 490 peer reviewed scientific papers (Hirsch Index: 94 Google scholar), co-inventor of more than 17 patent families (filed or submitted) of which 5 are in the (pre)commercialization phase and (co) promoter of more than 59 completed PhD’s (2 with cum laude). Prof. P. Lambin also has extensive experience with clinical trials. He is one of the inventors of “Radiomics” and “Distributed learning”, a revolutionary Big Data approach for Health care

    Michel Baijot

    Bioengineer
    Michel Baijot, PhD, is a bioengineer with over 25 years of experience in building biologicals businesses, making a significant contribution to strategy, licensing, M&A and technology transfer, with in-depth knowledge of developed and emerging markets. He is currently the CEO and Board Director of ASIT Biotech, and the Board Director of Radiomics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association for five years.
    Design: Erinas